Loading clinical trials...
Loading clinical trials...
A Prospective, Single-Center, Single-Arm Trial to Validate the Safety and Efficacy of "Dual-Conversion" Therapy With Liver Venous Deprivation (LVD), Conventional Transarterial Chemoembolization (cTACE), Tislelizumab, and Lenvatinib for Initially Unresectable Hepatocellular Carcinoma in the Right Liver.
Conditions
Interventions
Liver Venous Deprivation (LVD)
Conventional Transarterial Chemoembolization(C-TACE)
+1 more
Locations
1
China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Start Date
April 1, 2026
Primary Completion Date
December 30, 2027
Completion Date
June 30, 2028
Last Updated
March 18, 2026
Lead Sponsor
Hong Wu
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions